BioMark Partners With Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities

Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy comp

newsfileFeb 28 21:30

Theresa Peterson Joins Biomark's Advisory Team

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced-stage liquid biopsy company with a focus on

newsfileFeb 26 21:30

BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy compa

newsfileDec 29, 2023 21:30

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy compa

newsfileNov 28, 2023 21:30

BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

Dr. W. Randolph Ford, Ph.D., will be joining BioMark's Advisory team to support Artificial Intelligence and Machine Learning capabilities.Vancouver, British Columbia--(Newsfile Corp. - November 14, 20

newsfileNov 14, 2023 21:30

BioMark Announces Financial Contribution From the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company

newsfileNov 7, 2023 21:30